keyword
https://read.qxmd.com/read/38546225/chagas-disease-in-immunocompromised-patients
#21
REVIEW
Eva H Clark, Louisa A Messenger, Jeffrey D Whitman, Caryn Bern
SUMMARYAs Chagas disease remains prevalent in the Americas, it is important that healthcare professionals and researchers are aware of the screening, diagnosis, monitoring, and treatment recommendations for the populations of patients they care for and study. Management of Trypanosoma cruzi infection in immunocompromised hosts is challenging, particularly because, regardless of antitrypanosomal treatment status, immunocompromised patients with Chagas disease are at risk for T. cruzi reactivation, which can be lethal...
March 28, 2024: Clinical Microbiology Reviews
https://read.qxmd.com/read/38543824/torque-teno-virus-dna-load-in-blood-as-an-immune-status-biomarker-in-adult-hematological-patients-the-state-of-the-art-and-future-prospects
#22
REVIEW
Eliseo Albert, Estela Giménez, Rafael Hernani, José Luis Piñana, Carlos Solano, David Navarro
A solid body of scientific evidence supports the assumption that Torque teno virus (TTV) DNA load in the blood compartment may behave as a biomarker of immunosuppression in solid organ transplant recipients; in this clinical setting, high or increasing TTV DNA levels precede the occurrence of infectious complications, whereas the opposite anticipates the development of acute rejection. The potential clinical value of the TTV DNA load in blood to infer the risk of opportunistic viral infection or immune-related (i...
March 17, 2024: Viruses
https://read.qxmd.com/read/38543646/therapy-of-mycobacterium-abscessus-infections-in-solid-organ-transplant-patients
#23
REVIEW
Lubna Osman, Christopher Lopez, Yoichiro Natori, Shweta Anjan, Julia Bini Viotti, Jacques Simkins
Mycobacterium abscessus complex (MABC), a rapidly growing Mycobacterium , is one of the most common causes of non-tuberculous mycobacteria (NTM) infections in the United States of America, and it has been associated with a wide spectrum of infections in immunocompetent and immunosuppressed individuals. Eradicating MABC is very challenging, even with prolonged combination therapies. The management of MABC infections in solid organ transplant (SOT) patients is usually complex given their net state of immunosuppression, associated comorbidities, and potential drug-drug interactions, among other things...
March 16, 2024: Microorganisms
https://read.qxmd.com/read/38538455/epidemiology-of-cancer-in-kidney-transplant-recipients
#24
REVIEW
David Massicotte-Azarniouch, J Ariana Noel, Greg A Knoll
Kidney transplantation is the ideal treatment modality for patients with end-stage kidney disease, with excellent outcomes post-transplant compared with dialysis. However, kidney transplant recipients are at increased risk of infections and cancer because of the need for immunosuppression. Kidney transplant recipients have approximately two to three times greater risk of developing cancer than the general population, and cancer is a major contributor to morbidity and mortality. Most of the increased risk is driven by viral-mediated cancers such as post-transplant lymphoproliferative disorder, anogenital cancers, and Kaposi sarcoma...
March 26, 2024: Seminars in Nephrology
https://read.qxmd.com/read/38529910/policies-and-practice-of-solid-organ-donation-amongst-people-living-with-hiv-in-canada-time-for-education-and-re-evaluation
#25
REVIEW
Branka Vulesevic, Darren Lauscher, Deepali Kumar, Ruth Sapir-Pichhadze, Jean Tchervenkov, Jonathan B Angel, Cameron Wolfe, Cecilia T Costiniuk
The numbers of organ donors in Canada and the USA fall short of increasing demand, resulting in increased morbidity, poor health outcomes, higher medical costs and death of many individuals waitlisted for transplantation. In the US, since 2013 when the US HIV Organ Policy Equity (HOPE) Act lifted the ban on organ donation between people living with HIV, the option of using organs from People with HIV became a reality. In Canada, HIV diagnosis was an exclusion criterion to organ donation until 2017, when permission was granted if requirements for 'exceptional distribution' could be met...
February 24, 2024: HIV research & clinical practice
https://read.qxmd.com/read/38527780/prevention-of-cytomegalovirus-infection-in-solid-organ-transplant-recipients-guidelines-by-the-korean-society-of-infectious-diseases-and-the-korean-society-for-transplantation
#26
REVIEW
Kyungmin Huh, Sang-Oh Lee, Jungok Kim, Su Jin Lee, Pyoeng Gyun Choe, Ji-Man Kang, Jaeseok Yang, Heungsup Sung, Si-Ho Kim, Chisook Moon, Hyeri Seok, Hye Jin Shi, Yu Mi Wi, Su Jin Jeong, Wan Beom Park, Youn Jeong Kim, Jongman Kim, Hyung Joon Ahn, Nam Joong Kim, Kyong Ran Peck, Myoung Soo Kim, Sang Il Kim
Cytomegalovirus (CMV) is the most important opportunistic viral pathogen in solid organ transplant (SOT) recipients. The Korean guideline for the prevention of CMV infection in SOT recipients was developed jointly by the Korean Society for Infectious Diseases and the Korean Society of Transplantation. CMV serostatus of both donors and recipients should be screened before transplantation to best assess the risk of CMV infection after SOT. Seronegative recipients receiving organs from seropositive donors face the highest risk, followed by seropositive recipients...
March 12, 2024: Infection & Chemotherapy
https://read.qxmd.com/read/38526183/presentation-anagement-and-outcomes-of-norovirus-in-adult-and-pediatric-solid-organ-and-hematopoietic-stem-cell-transplant-recipients-a-multicenter-retrospective-study
#27
JOURNAL ARTICLE
Michelle Callegari, Lara A Danziger-Isakov, Anne Rose, Daniel Kaul, Kelly Shaffer, Pearlie P Chong, Diana Florescu, Kaci German, Robin Avery, M Hong Nguyen, Brett Wildfeuer, Marian G Michaels, Michael Green, Kexin Guo, Lihui Zhao, Amna Daud, Michael G Ison
BACKGROUND: Norovirus (NoV) can cause chronic relapsing and remitting diarrhea in immunocompromised patients.  Few multicenter studies have described the clinical course, outcomes, and complications of chronic NoV in transplant recipients. METHODS: A multicenter retrospective study of adult and pediatric SOT and HSCT recipients diagnosed with NoV between November 1, 2017, and February 28, 2021. Data were obtained from electronic medical records (EMR) and entered into a central REDCap database...
March 25, 2024: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://read.qxmd.com/read/38525759/hemophagocytic-lymphohistiocytosis-hlh-in-patients-with-tick-borne-illness-a-scoping-review-of-98-cases
#28
REVIEW
Dorde Jevtic, Marilia Dagnon da Silva, Alberto Busmail Haylock, Charles W Nordstrom, Stevan Oluic, Nikola Pantic, Milan Nikolajevic, Nikola Nikolajevic, Magdalena Kotseva, Igor Dumic
Hemophagocytic lymphohistiocytosis (HLH) secondary to tick-borne infections is a rare but potentially life-threatening syndrome. We performed a scoping review according to PRISMA guidelines to systematically analyze the existing literature on the topic. A total of 98 patients were included, with a mean age of 43.7 years, of which 64% were men. Most cases, 31%, were reported from the USA. Immunosuppression was present in 21.4%, with the most common cause being previous solid organ transplantation. Constitutional symptoms were the most common, observed in 83...
February 21, 2024: Infectious Disease Reports
https://read.qxmd.com/read/38524259/chronic-hepatitis-e-virus-manifesting-as-elevated-transaminases-in-a-heart-transplant-patient
#29
Islam Mohamed, Kimberly Sanders, Donald J Hillebrand
Hepatitis E virus (HEV) is a common cause of viral hepatitis worldwide. Genotypes 1 and 2 cause acute hepatitis in endemic regions (Asia and Africa), whereas genotypes 3 and 4 (America and Europe) result in sporadic acute or chronic hepatitis, specifically in certain groups. HEV infections are rising because of increased transplantation rates and immunosuppression. We report a 75-year-old heart transplant patient with nonspecific symptoms, diagnosed with HEV chronic hepatitis. Despite ribavirin-induced hemolytic anemia, the patient achieved sustained virological response and normalization of liver enzymes...
March 2024: ACG Case Reports Journal
https://read.qxmd.com/read/38523030/advancing-immunosuppression-in-liver-transplantation-a-narrative-review
#30
REVIEW
Samuele Iesari, Francesca Laura Nava, Ilaria Elena Zais, Laurent Coubeau, Mariano Ferraresso, Evaldo Favi, Jan Lerut
Immunosuppression is essential to ensure recipient and graft survivals after liver transplantation (LT). However, our understanding and management of the immune system remain suboptimal. Current immunosuppressive therapy cannot selectively inhibit the graft-specific immune response and entails a significant risk of serious side effects, i.e., among others, de novo cancers, infections, cardiovascular events, renal failure, metabolic syndrome, and late graft fibrosis, with progressive loss of graft function. Pharmacological research, aimed to develop alternative immunosuppressive agents in LT, is behind other solid-organ transplantation subspecialties, and, therefore, the development of new compounds and strategies should get priority in LT...
March 16, 2024: Hepatobiliary & Pancreatic Diseases International: HBPD INT
https://read.qxmd.com/read/38521447/the-successful-treatment-of-mpox-with-brincidofovir-in-renal-transplant-recipients-a-report-of-2-cases
#31
Reem M Alameer, Amani Yamani, Abdulrahman Al-Saud, Sultan Alsobayeg, Bayan Alamro, Alaa Alali, Ehab Hammad, Ali M Shendi, Reem S Almaghrabi
An mpox outbreak was declared in July 2022 by the world health organization (WHO). It causes a mild self-limiting disease however; in immunosuppressed hosts, it tends to cause severe disseminated infection. Most cases of mpox in sold organ transplant (SOT) recipients reported in the literature were treated with Tecovirimat. Here we report two cases of severe disseminated mpox infection in renal transplant recipients that were successfully treated with Brincidofovir. Both patients were discharged from the hospital with no immediate significant side effects from Brincidofovir reported until the submission of this report...
March 21, 2024: International Journal of Infectious Diseases: IJID
https://read.qxmd.com/read/38517571/molecular-monitoring-of-viral-infections-in-immunocompromised-patients-in-a-large-university-hospital-in-italy-reflections-after-thirteen-years-of-real-life-activity
#32
JOURNAL ARTICLE
Lilia Cinti, Piergiorgio Roberto, Matteo Rossi, Anna Napoli, Gianluca Russo, Anna Paola Iori, Giuseppe Gentile, Maria Augurusa, Corrado Girmenia, Guido Antonelli, Aurelia Gaeta
PURPOSE: This study aimed to investigate the prevalence and viral reactivations of clinical interest in the immunocompromised patient with particular focus on hematologic and solid organ transplant recipients. METHODS: Molecular screening data of CMV, EBV, JCV and BKV from 2011 to 2023 were analyzed. This extensive time span allowed the access to more than 100,000 samples from over 20,000 patients treated at Policlinico Umberto I. It was possible to temporally investigate patient attendance patterns, average age distribution, seasonality of infections, and positivity rates of the analyzed viruses...
March 22, 2024: European Journal of Clinical Microbiology & Infectious Diseases
https://read.qxmd.com/read/38516923/epidemiology-and-outcomes-associated-with-enterococcal-blood-stream-infection-among-liver-and-kidney-transplant-recipients
#33
JOURNAL ARTICLE
Kevin D He, Syed Suhaib Naqvi, Vanessa L Cowan, Conor M Stack, Carolyn D Alonso, Barbra M Blair
Bloodstream infections (BSIs) account for 18% of bacterial infections in the first year after solid organ transplantation (SOT). Enterococcus accounts for up to 20% of BSIs in this population, with vancomycin-resistant enterococcus (VRE) posing a particular risk. This is a retrospective, case-control study of adult liver and kidney transplant recipients between 01/01/2016 and 06/30/2021 that characterizes the epidemiology and outcomes of enterococcal BSIs in liver and kidney transplantations at a single institution...
March 2024: Clinical Transplantation
https://read.qxmd.com/read/38515768/primary-central-nervous-system-post-transplantation-lymphoproliferative-disorder-a-case-report-and-systematic-review-of-imaging-findings
#34
Dylan Hoyt, Jeremy Hughes, John Liu, Hashem Ayyad
Primary central nervous system post-transplant lymphoproliferative disease (PCNS-PTLD) is a rare subset of post-transplant lymphoproliferative disorder (PTLD) isolated to the CNS without nodal or extra-nodal organ involvement [1,2]. PCNS-PTLD occurs primarily in patients following either solid organ transplants or hematopoietic stem cell transplants and tends to be monomorphic DLBCL. The development of PCNS-PTLD is commonly associated with EBV infection [3]. Many intracranial pathologies can resemble the imaging appearance of PCNS-PTLD, including primary CNS lymphoma, glial tumors, metastatic disease, and intracranial abscesses...
June 2024: Radiology Case Reports
https://read.qxmd.com/read/38513747/efficacy-of-ceftazidime-avibactam-in-the-treatment-of-carbapenem-resistant-klebsiella-pneumoniae-infections-focus-on-solid-organ-transplantation-recipients
#35
JOURNAL ARTICLE
Juan Hu, Lei Zha, Yong-Wei Yu, Qun Su, Xue-Ling Fang, Jin-Ru Ji, Ping Shen, Yun- Bo Chen, Xia Zheng, Yong-Hong Xiao
INTRODUCTION: Ceftazidime-avibactam (CAZ-AVI) is a new option to treat KPC- and OXA-48 carbapenem-resistant Klebsiella pneumoniae (CRKP) infections. However, clinical evidence is limited regarding its use in treating CRKP infections, especially in solid organ transplantation (SOT) recipients. In this study, we assessed the efficacy of CAZ-AVI in treating CRKP infections in both the general population and the SOT recipients in comparison with other antibiotic regimens. METHODS: This is a single-center retrospective cohort study of patients admitted between January 1, 2018 and June 30, 2021 with the diagnosis of CRKP infections receiving either CAZ-AVI or other regimens ≥ 72 hours and clinical outcomes were analyzed...
March 19, 2024: International Journal of Antimicrobial Agents
https://read.qxmd.com/read/38505578/colonic-malakoplakia-in-a-pediatric-renal-transplant-recipient-case-report
#36
Kristen G Valencia Deray, Richard Kellermayer, Alexis C Gomez, Kalyani R Patel, Peace Imani, Seiji Kitagawa, Claire E Bocchini, Alvaro Orjuela
Malakoplakia is a rare, chronic granulomatous disease that mainly affects the genitourinary system of immunocompromised adults. It is caused by a bactericidal deficit in macrophages and, therefore, the treatment includes antimicrobials that reach high concentrations in macrophages. To our knowledge, we present the first case of malakoplakia in a pediatric solid organ transplant recipient. Our patient is a 15-year-old male renal transplant recipient who presented with recurrent diarrhea. Blood, urine, and gastrointestinal pathogen panel testing were positive for enteroaggregative Escherichia coli...
2024: SAGE Open Medical Case Reports
https://read.qxmd.com/read/38505248/hepatitis-e-virus-hev-infection-among-immunocompromised-individuals-a-brief-narrative-review
#37
REVIEW
Radostina Alexandrova, Ilia Tsachev, Plamen Kirov, Abedulkadir Abudalleh, Hristo Hristov, Tanya Zhivkova, Lora Dyakova, Magdalena Baymakova
Hepatitis E virus (HEV) is a single-stranded positive-sense RNA virus that belongs to Hepeviridae family. HEV is the most common cause of acute viral hepatitis worldwide. According to the World Health Organization (WHO), there are estimated 20 million HEV infections worldwide every year, leading to estimated 3.3 million symptomatic cases of HEV infection. The WHO estimates that HEV infection caused approximately 44,000 deaths in 2015, which represents 3.3% of mortality rates due to viral hepatitis. In low-income (LI) countries and lower-middle-income (LMI) countries, HEV is a waterborne infection induced by HEV genotype (gt) 1 and HEV gt 2 that cause large outbreaks and affect young individuals with a high mortality rate in pregnant women from South Asian countries and patients with liver diseases...
2024: Infection and Drug Resistance
https://read.qxmd.com/read/38501790/histoplasma-capsulatum-tenosynovitis-an-unusual-presentation-in-a-kidney-transplant-recipient
#38
JOURNAL ARTICLE
Jhongert Alza-Arcila, Isabel Cristina Ramírez-Sánchez, Ricardo Augusto Diaz-Sanabria
Histoplasmosis is an expected endemic mycosis in solid organ transplant recipients and occurs as a primary infection, reactivation, or, rarely, acquired from an infected allograft. Reactivation is favored by maintenance immunosuppression or anti-rejection therapy, which facilitates the appearance of disseminated forms as well as unusual presentations. We present the case of a 66-year-old woman with isolated tenosynovitis due to Histoplasma capsulatum 25 years after a kidney transplant.
March 19, 2024: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://read.qxmd.com/read/38501337/convalescent-plasma-therapy-in-immunocompromised-patients-infected-with-the-ba-1-or-ba-2-omicron-sars-cov-2
#39
JOURNAL ARTICLE
Quentin Richier, Benjamin De Valence, Dorothée Chopin, Emmanuelle Gras, Laura I Levi, Yasmine Abi Aad, Jérôme Pacanowski, Jean-Luc Meynard, Léo Plaçais, Dorothée Fey, Priscille Couture, Guillaume Martin-Blondel, Vincent Pestre, Juliette Woessner, Sophie Ancellin, Pierre Weyrich, Benjamin Carpentier, Salim Idri, Pierre Tiberghien, Laure Surgers, Thomas Hueso, Karine Lacombe
The emergence of SARS-CoV-2 Omicron variant has led to a complete reconfiguration of the therapeutic landscape, with all monoclonal antibodies having lost any neutralization activity. We report here a case series of 75 immunocompromised patients infected by the Omicron variant who benefited from COVID-19 convalescent plasma (CCP). At Day 28, the overall survival was 76% (95% CI 67-86) with no significant difference in the clinical outcome between patients with hematological malignancies, solid organ transplantation or autoimmune diseases...
March 2024: Influenza and Other Respiratory Viruses
https://read.qxmd.com/read/38501003/seroprevalence-of-sars-cov-2-igg-in-people-with-cystic-fibrosis
#40
JOURNAL ARTICLE
Kathleen Mahan, Sarah Kiel, Rebecca Freese, Nicholas Marka, Jordan Dunitz, Joanne Billings
BACKGROUND: When the first known US case of COVID-19 (Coronavirus Disease 2019) was reported in early 2020, little was known about the impact of this novel virus on the cystic fibrosis community. As the majority of individuals with CF have chronic lung disease, this population was initially considered to be at high risk for severe disease as infection with a multitude of viruses has proven to cause pulmonary exacerbation. SARS-CoV-2 virus has proven challenging to study given the multiple disease manifestations, range of severity, and wave-like phenomenon that varies geographically...
March 30, 2024: Heliyon
keyword
keyword
80337
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.